Skip to content

Application of oxycodone-propofol combination in anesthesia for endoscopic mucosal resection (EMR)

Application of oxycodone-propofol combination in anesthesia for endoscopic mucosal resection (EMR)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126818
Enrollment
Unknown
Registered
2026-06-16
Start date
2026-03-19
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endoscopic Therapy

Interventions

Group O:Group O received oliceridine 0.02 mg/kg combined with propofol 1.5 mg/kg
Group S:Group S received sufentanil 0.1 µg/kg combined with propofol 1.5 mg/kg

Sponsors

Lu'an Hospital Affiliated to Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients must be between 18 and 65 years of age, with no gender restrictions; 2. Body mass index must be within the range of 18 to 30 kilograms per square meter; 3. American Society of Anesthesiologists physical status classification must be Class I, II, or III ; 4. Scheduled to undergo painless endoscopic mucosal resection (EMR) of the gastrointestinal tract under general anesthesia; 5. Must provide written informed consent prior to participation, indicating voluntary agreement to take part in the study.

Exclusion criteria

Exclusion criteria: 1. Individuals with any contraindication to general anesthesia are excluded from the study 2. Patients who have a known allergy to or contraindication against any of the study medications (including opioids)o r their ingredients will not be enrolled 3. Exclusion applies to patients with a history of craniocerebral trauma, cerebrovascular accidents, or those diagnosed with central nervous system disorders or mental illnesses 4. Patients on chronic therapy with psychotropic agents, opioid analgesics, sedative-hypnotic medications, or non-steroidal anti-inflammatory drugs are ineligible 5. Any patient assessed as having a difficult airway by the attending anesthesiologist will be excluded 6. Subjects who have taken part in another clinical investigation in the 3-month period preceding the current study enrollment are not eligible to participate

Design outcomes

Primary

MeasureTime frame
Incidence of opioid-induced respiratory depression;visual analogue scale (VAS);QoR15 Scale;

Secondary

MeasureTime frame
Hemodynamic parameters (MAP, HR, SpO2);Incidence of adverse events;

Countries

China

Contacts

Public ContactXu Zhonghou

Lu'an Hospital Affiliated to Anhui Medical University

2056161554@qq.com+86 139 6549 4791

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 29, 2026